Intec Pharma Ltd (NASDAQ:NTEC) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokers have set a 1-year consensus price objective of $9.25 for the company and are anticipating that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also given Intec Pharma an industry rank of 105 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research upgraded Intec Pharma from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Thursday, September 8th.

A number of institutional investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. bought a new position in Intec Pharma during the second quarter worth about $2,277,000. Opaleye Management Inc. increased its position in shares of Intec Pharma by 1.3% in the first quarter. Opaleye Management Inc. now owns 638,000 shares of the company’s stock worth $2,629,000 after buying an additional 8,000 shares during the last quarter. Finally, Sabby Management LLC increased its position in shares of Intec Pharma by 6.5% in the first quarter. Sabby Management LLC now owns 714,062 shares of the company’s stock worth $2,949,000 after buying an additional 43,613 shares during the last quarter.

Intec Pharma (NASDAQ:NTEC) traded down 5.86% on Thursday, hitting $5.46. The stock had a trading volume of 14,449 shares. The company has a 50-day moving average price of $5.98 and a 200-day moving average price of $4.75. Intec Pharma has a 52 week low of $3.03 and a 52 week high of $6.36. The stock’s market capitalization is $62.24 million.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

5 Day Chart for NASDAQ:NTEC

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with's FREE daily email newsletter.